Five COVID-19 vaccines have been approved for emergency use
On the evening of December 1 and December 3, including Livzon Group (000513SZ) and CanSino (688185SH) and other five listed companies have successively issued announcements saying that the company's newly developed new crown vaccine has been included in the emergency use. The five vaccines designated for emergency use all highlight their protective efficacy against the XBB variant, the dominant local circulating strain.
On the 24th of last month, the ** Joint Prevention and Control Mechanism issued a notice, requiring all localities to do a good job in the prevention and control of new coronavirus infection and other key infectious diseases in winter and spring. According to the notice, winter and spring are the seasons of high incidence of infectious diseases such as new crown, influenza, norovirus gastroenteritis, and diseases such as Mycoplasma pneumoniae infection. At present, the situation of the new crown epidemic in the country is generally stable, but there is still a risk of the new crown epidemic in China in winter.
On the evening of December 3, Livzon Group and CanSino successively disclosed the information that the new crown vaccine developed and produced by the company was approved for emergency use. According to Livzon Group, the recombinant novel coronavirus fusion protein bivalent (prototype strain omicronxbb variant) vaccine (CHO cell) developed and produced by Livzon has a positive effect on EG5.1、xbb.1.9.1、xbb.1.16、xbb.1.5 and other epidemic variants have a broad-spectrum neutralization effect, suggesting that this product has a good protective effect against the current major epidemic strains. CanSino announced that the new crown XBB1.The 5-variant vaccine will help update immunization strategies and provide better protection for the population.
Previously, on the evening of December 1, New Nova (300765SZ), Watson Biotech (300142SZ), Shenzhou Cell-U (688520SH) also disclosed information that its self-developed coronavirus vaccine has been approved for emergency use.
New Novi said, sys600632 is for xbb1.5 mRNA vaccines representing the dominant variants. Walvax said that the RQ3033 vaccine developed by the company is a monovalent vaccine designed for the current new coronavirus omicronxbb, which is in line with the latest recommendation of the World Health Organization to give preference to monovalent new crown vaccines containing omicronxbb antigen components. Shenzhou Cell said that the company's self-developed recombinant new coronavirus beta omicron (BA1/bq.1.1/xbb.1) Variant S trimer protein vaccine (project code: SCTV01E-2) replaces the alpha and delta variants of the early variants with the current major circulating variant BQ1.1 and xbb1 of the S trimer protein antigen constitutes an iterative COVID-19 vaccine to enhance the pertinence and broad-spectrum response to multiple current major circulating strains and their sub-variants.
Before the above-mentioned five new vaccines were approved for emergency use, Chengdu WestVac's recombinant trivalent XBB new coronavirus trimer protein vaccine has been officially launched in many places across the country recently.
The XBB series of variants is still the local epidemic strain in China. According to the latest information on the official website of the China Disease Control and Prevention, in October 2023, a total of 7,646 local cases of new coronavirus genome valid sequences were reported from 31 provinces (autonomous regions and municipalities directly under the central government) and the Xinjiang Production and Construction Corps, all of which were Omicron variants, covering 73 evolutionary branches, and the main epidemic strain was the XBB series variant. According to the sampling date, the proportion of XBB and its subclades continues to be high, reaching 100 in the 43rd week of 2023 (October 23-October 29).0%。
*: Changjiang Cloud News.
Editor: Qiao Hong Proofreader: Chen Long.